GLP-1 agonist

The speaker advocates for keeping patients at the lowest effective GLP-1 dose rather than the highest tolerated dose. He claims this approach results in slower weight loss but superior long-term weight maintenance. This is presented as a clinical practice philosophy without reference to specific dosages, titration schedules, or supporting studies.

The speaker warns that stopping or reducing a GLP-1 dose — which he says 'almost always happens for one reason or another' — leads to severe rebound weight gain. This is framed as a predictable consequence of high-dose protocols that do not build sustainable habits. No clinical data or study citations are provided.

The speaker asserts that all five warning signs of excessive GLP-1 dosing share a common root cause: the patient is under-eating and physiologically over-stressed. This is presented as a clinical framework rather than a cited mechanism from literature. No specific caloric thresholds or biomarkers are mentioned.

The speaker warns that excessive GLP-1 dosing leads to muscle loss rather than fat loss, resulting in a 'skinny fat' appearance where the scale moves but body composition worsens. This is attributed to under-eating and over-stress on the body. No body composition metrics, dosages, or study references are cited.

Hair shedding is listed as a fourth sign that a patient's GLP-1 dose is too high. The speaker implies this is a downstream consequence of under-eating and physiological stress caused by excessive appetite suppression. No mechanism, timeline, or dosage context is provided.

Excessive GLP-1 dosing is associated with severe fatigue and low energy, described as operating in 'battery saving mode.' The speaker attributes this to under-eating driven by over-suppressed appetite. No specific dosage levels or lab markers are referenced.

The speaker describes a state he calls 'zombie mode' where patients on excessive GLP-1 doses experience neither cravings nor satisfaction from food. This anhedonic relationship with eating is framed as a warning sign of over-suppression of appetite signaling. No mechanistic explanation or dosage is provided.

The speaker claims that nausea every time a patient eats is a primary sign that their GLP-1 dose is too high. This is presented as a clinical observation from patient management. No specific dosage thresholds or drug names are cited.